Articles from NeXtGen Biologics

GAINESVILLE, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics is pleased to report that the USPTO declined to initiate Inter Partes Review (“IPR”), following the filing by RegenX Science of two IPR Petitions in February 2025 requesting the cancellation of certain claims in NeXtGen’s US Patent Nos. 10,617,790 and 11,660,376, leaving the patents intact and fully enforceable. RegenX Science was formerly a licensee under these patents.

PENSACOLA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lovell® Government Services and NeXtGen™ Biologics, Inc., a medical device company that manufactures NeoMatriX®, announced today that they have partnered to serve federal healthcare, including the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as NeXtGen’s Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems. 

GAINESVILLE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics announced today the successful completion of a two-day inspection by the U.S. Food and Drug Administration (FDA). The inspection concluded with no Form 483 observations issued, underscoring the company’s commitment to quality, compliance, and operational excellence.

GAINESVILLE, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics announces the issuance of a third U.S. patent, US12311079, on May 27, 2025, as part of its suite of U.S. and foreign patents directed to extracellular matrix components derived from a highly regenerative, non-mammalian species, namely axolotls, a urodele amphibian. In addition to our previous patents1, the most recent patent is directed to a tissue culture system that provides patent coverage for two conditioned media and ECM, and methods of use of these products.